Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2014

01-08-2014 | Epidemiology

Long-term cognitive function change among breast cancer survivors

Authors: Ying Zheng, Jianfeng Luo, Pingping Bao, Hui Cai, Zhen Hong, Ding Ding, James C. Jackson, Xiao-Ou Shu, Qi Dai

Published in: Breast Cancer Research and Treatment | Issue 3/2014

Login to get access

Abstract

Cognitive decline is a common health problem among breast cancer patients and understanding trajectories of cognitive change following among breast cancer survivors is an important public health goal. We conducted a longitudinal study to investigate the cognitive function changes from 18 month to 3 years after breast cancer diagnosis among participants of the Shanghai Breast cancer survivor study, a population-based cohort study of breast cancer survivors. In our study, we completed cognitive function evaluation for 1,300 breast cancer survivors at the 18th month’s survey and 1,059 at 36th month’s survey, respectively, using a battery of cognitive function measurements. We found the scores in attention and executive function, immediate memory and delayed memory significantly improved from 18 to 36 months after breast cancer diagnosis. The improvements appeared in breast cancer survivors receiving treatments (i.e., surgery, radiotherapy, tamoxifen, or chemotherapy combined with or without tamoxifen), but not in those who received neither chemotherapy nor tamoxifen treatment. The results indicate that cognitive functions, particularly immediate verbal episodic memory, and delayed memory significantly improved among breast cancer survivors from 18 to 36 months after cancer diagnosis. In general, comorbidity was inversely associated with the improvements.
Literature
1.
go back to reference Boyle P, Levin B (eds) (2008) World Cancer Report. International Agency for Research on Cancer, Lyon Boyle P, Levin B (eds) (2008) World Cancer Report. International Agency for Research on Cancer, Lyon
2.
go back to reference Brenner H (2002) Long-term survival rates of cancer survivors achieved by the end of the 20th century: a period analysis. Lancet 360(1131–1135):2002 Brenner H (2002) Long-term survival rates of cancer survivors achieved by the end of the 20th century: a period analysis. Lancet 360(1131–1135):2002
4.
go back to reference Wefel JS, Meyers CA (2005) Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 97:788–789PubMedCrossRef Wefel JS, Meyers CA (2005) Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 97:788–789PubMedCrossRef
5.
go back to reference Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299PubMedCrossRef Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299PubMedCrossRef
6.
go back to reference Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-oncology 15:422–430PubMedCrossRef Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-oncology 15:422–430PubMedCrossRef
7.
go back to reference Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834PubMedCentralPubMedCrossRef Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834PubMedCentralPubMedCrossRef
8.
go back to reference Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer–preliminary results of an observational longitudinal study. Breast 14:142–150PubMedCrossRef Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D (2005) The effects of adjuvant chemotherapy on cognition in women with breast cancer–preliminary results of an observational longitudinal study. Breast 14:142–150PubMedCrossRef
9.
go back to reference Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL (2001) Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 21:407–424PubMedCrossRef Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL (2001) Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage 21:407–424PubMedCrossRef
10.
11.
12.
go back to reference Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463PubMedCrossRef Vardy J, Rourke S, Tannock IF (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25:2455–2463PubMedCrossRef
13.
go back to reference Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP (2011) Either called ‘Chemobrain’ or ‘Chemofog’, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 41:126–139CrossRef Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP (2011) Either called ‘Chemobrain’ or ‘Chemofog’, the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 41:126–139CrossRef
14.
go back to reference McAllister TW, Ahles TA, Saykin AJ, Ferguson RJ, McDonald BC, Lewis LD, Flashman LA, Rhodes CH (2004) Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep 6:364–371PubMedCrossRef McAllister TW, Ahles TA, Saykin AJ, Ferguson RJ, McDonald BC, Lewis LD, Flashman LA, Rhodes CH (2004) Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep 6:364–371PubMedCrossRef
15.
go back to reference Barton D, Loprinzi C (2002) Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer 3:S121–S127PubMedCrossRef Barton D, Loprinzi C (2002) Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer 3:S121–S127PubMedCrossRef
16.
go back to reference Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, Klaunig JE, Champion VL, Unverzagt FW, Saykin AJ (2013) Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 137:493–502PubMedCentralPubMedCrossRef Conroy SK, McDonald BC, Smith DJ, Moser LR, West JD, Kamendulis LM, Klaunig JE, Champion VL, Unverzagt FW, Saykin AJ (2013) Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 137:493–502PubMedCentralPubMedCrossRef
17.
go back to reference Reuter-Lorenz PA, Cimprich B (2013) Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat 137:33–43PubMedCrossRef Reuter-Lorenz PA, Cimprich B (2013) Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat 137:33–43PubMedCrossRef
18.
go back to reference Avisar A, River Y, Schiff E, Bar-Sela G, Steiner M, Ben-Arye E (2012) Chemotherapy-related cognitive impairment: does integrating complementary medicine have something to add? review of the literature. Breast Cancer Res Treat 136:1–7PubMedCrossRef Avisar A, River Y, Schiff E, Bar-Sela G, Steiner M, Ben-Arye E (2012) Chemotherapy-related cognitive impairment: does integrating complementary medicine have something to add? review of the literature. Breast Cancer Res Treat 136:1–7PubMedCrossRef
19.
go back to reference Mar Helen G, Fan Nadine Houédé-Tchen, Yi Qi-Long, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032CrossRef Mar Helen G, Fan Nadine Houédé-Tchen, Yi Qi-Long, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032CrossRef
20.
go back to reference Chen Xiaoli, Wei Lu, Ying Zheng GuK, Chen Z, Zheng W, Shu XO (2010) Exercise, tea consumption, and depression among breast cancer survivors. J Clin Oncol 28:991–998PubMedCentralPubMedCrossRef Chen Xiaoli, Wei Lu, Ying Zheng GuK, Chen Z, Zheng W, Shu XO (2010) Exercise, tea consumption, and depression among breast cancer survivors. J Clin Oncol 28:991–998PubMedCentralPubMedCrossRef
21.
go back to reference Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, Lu W, Shu XO (2011) Quality of Life after Breast Cancer Diagnosis and Survival. J Clin Oncol 29:406–412PubMedCentralPubMedCrossRef Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, Lu W, Shu XO (2011) Quality of Life after Breast Cancer Diagnosis and Survival. J Clin Oncol 29:406–412PubMedCentralPubMedCrossRef
22.
go back to reference Salmon DP, Jin H, Zhang M, Grantc I, Yud E (1995) Neuropsychological assessment of Chinese elderly in the Shanghai Dementia survey. Clin Neuropsychol 9:159–168CrossRef Salmon DP, Jin H, Zhang M, Grantc I, Yud E (1995) Neuropsychological assessment of Chinese elderly in the Shanghai Dementia survey. Clin Neuropsychol 9:159–168CrossRef
23.
go back to reference Chan AS, Poon MW (1999) Performance of 7- to 95-year-old individuals in a Chinese version of the category fluency test. J Int Neuropsychol Soc 5:525–533PubMedCrossRef Chan AS, Poon MW (1999) Performance of 7- to 95-year-old individuals in a Chinese version of the category fluency test. J Int Neuropsychol Soc 5:525–533PubMedCrossRef
24.
go back to reference Lee TM, Chan CC (2000) Stroop interference in Chinese and English. J Clin Exp Neuropsychol 22:465–471PubMedCrossRef Lee TM, Chan CC (2000) Stroop interference in Chinese and English. J Clin Exp Neuropsychol 22:465–471PubMedCrossRef
25.
go back to reference He J, Iosif AM, Lee DY, Martinez O, Ding D, Carmichael O, Mortimer JA, Zhao QH, Chu SG, Guo QH et al (2010) Brain morphology and cerebrovascular risk in mild cognitive impairment and dementia: sCOBHI-P study. Arch Neurol 67:1231–1237PubMedCentralPubMedCrossRef He J, Iosif AM, Lee DY, Martinez O, Ding D, Carmichael O, Mortimer JA, Zhao QH, Chu SG, Guo QH et al (2010) Brain morphology and cerebrovascular risk in mild cognitive impairment and dementia: sCOBHI-P study. Arch Neurol 67:1231–1237PubMedCentralPubMedCrossRef
26.
go back to reference Bano D, Agostini M, Melino G, Nicotera P (2011) Ageing, neuronal connectivity and brain disorders: an unsolved ripple effect. Mol Neurobiol. 43:124–130PubMedCrossRef Bano D, Agostini M, Melino G, Nicotera P (2011) Ageing, neuronal connectivity and brain disorders: an unsolved ripple effect. Mol Neurobiol. 43:124–130PubMedCrossRef
27.
go back to reference Cullum S, Huppert FA, McGee M, Dening T, Ahmed A, Paykel ES, Brayne C (2000) Decline across different domains of cognitive function in normal ageing: results of a longitudinal population-based study using CAMCOG. Int J Geriatr Psychiatry 15:853–862PubMedCrossRef Cullum S, Huppert FA, McGee M, Dening T, Ahmed A, Paykel ES, Brayne C (2000) Decline across different domains of cognitive function in normal ageing: results of a longitudinal population-based study using CAMCOG. Int J Geriatr Psychiatry 15:853–862PubMedCrossRef
28.
29.
go back to reference Klepin H, Mohile S, Hurria A (2009) Geriatric assessment in older survivors with breast cancer. J Natl Compr Cancer Netw 7:226–236 Klepin H, Mohile S, Hurria A (2009) Geriatric assessment in older survivors with breast cancer. J Natl Compr Cancer Netw 7:226–236
30.
go back to reference Mitsiades N, Correa D, Gross CP, Hurria A, Slovin SF (2008) Cognitive effects of hormonal therapy in older adults. Semin Oncol 35:569–581PubMedCrossRef Mitsiades N, Correa D, Gross CP, Hurria A, Slovin SF (2008) Cognitive effects of hormonal therapy in older adults. Semin Oncol 35:569–581PubMedCrossRef
31.
go back to reference Rossi A, Colantuoni G, Maione P, Ferrara C Airoma, G, Barzelloni, M. L., Castaldo, V, Gridelli, C, (2005) Chemotherapy of breast cancer in the elderly. Curr Med Chem 12:297–310PubMedCrossRef Rossi A, Colantuoni G, Maione P, Ferrara C Airoma, G, Barzelloni, M. L., Castaldo, V, Gridelli, C, (2005) Chemotherapy of breast cancer in the elderly. Curr Med Chem 12:297–310PubMedCrossRef
32.
go back to reference Bourbonniere M, Kagan SH (2004) Nursing intervention and older adults who have cancer: specific science and evidence based practice. Nurs Clin North Am 39:529–543PubMedCrossRef Bourbonniere M, Kagan SH (2004) Nursing intervention and older adults who have cancer: specific science and evidence based practice. Nurs Clin North Am 39:529–543PubMedCrossRef
33.
go back to reference Vodermaier A (2009) Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health 5:503–516 Vodermaier A (2009) Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health 5:503–516
34.
go back to reference Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440PubMedCentralPubMedCrossRef Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440PubMedCentralPubMedCrossRef
Metadata
Title
Long-term cognitive function change among breast cancer survivors
Authors
Ying Zheng
Jianfeng Luo
Pingping Bao
Hui Cai
Zhen Hong
Ding Ding
James C. Jackson
Xiao-Ou Shu
Qi Dai
Publication date
01-08-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3044-1

Other articles of this Issue 3/2014

Breast Cancer Research and Treatment 3/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine